Europeiska unionen - italienska - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilato - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - agenti antineoplastici - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. i pazienti che hanno un basso o bassissimo rischio di recidiva non dovrebbero ricevere il trattamento adiuvante. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. tranne che nel recente diagnosi di lmc in fase cronica, non ci sono studi clinici controllati che dimostrano un beneficio clinico o un aumento della sopravvivenza per queste malattie.

Italien - italienska - Ministero della Salute

ceva salute animale s.p.a. - altrenogest - altrenogest - 4 millilitro (i), altrenogest - 4 ml, altrenogest - 4 mg/ml - altrenogest

Italien - italienska - AIFA (Agenzia Italiana del Farmaco)

noridem enterprises ltd - deferoxamina - deferoxamina

Italien - italienska - AIFA (Agenzia Italiana del Farmaco)

mylan s.p.a. - levodopa, inibitori della decarbossilasi e inibitori della comt - levodopa, inibitori della decarbossilasi e inibitori della comt

Italien - italienska - Ministero della Salute

krka dd novo mesto - marbofloxacina - marbofloxacina - 20 milligrammo (i), marbofloxacina - 5 milligrammo (i), marbofloxacina - 80 mg, marbofloxacina - 20 mg, marbofloxacina - 5 mg - marbofloxacin

Italien - italienska - AIFA (Agenzia Italiana del Farmaco)

teva italia s.r.l. - fludarabina - fludarabina

Italien - italienska - AIFA (Agenzia Italiana del Farmaco)

accord healthcare, s.l.u. - fludarabina - fludarabina

Europeiska unionen - italienska - EMA (European Medicines Agency)

mylan s.a.s. - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - agenti antineoplastici - trattamento del carcinoma mammario, forme speciali di cancro ai polmoni (carcinoma polmonare non a piccole cellule), cancro alla prostata, cancro gastrico o carcinoma della testa e del collo.

Italien - italienska - AIFA (Agenzia Italiana del Farmaco)

pfizer italia s.r.l. - lincomicina - lincomicina

Italien - italienska - AIFA (Agenzia Italiana del Farmaco)

pfizer italia s.r.l. - pirimetamina, associazioni - pirimetamina, associazioni